Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H13NO5S2 |
| Molecular Weight | 267.323 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CSCC(=O)NC(CCS)C(O)=O
InChI
InChIKey=JXVPSTRNHZDJFF-UHFFFAOYSA-N
InChI=1S/C8H13NO5S2/c10-6(3-16-4-7(11)12)9-5(1-2-15)8(13)14/h5,15H,1-4H2,(H,9,10)(H,11,12)(H,13,14)
| Molecular Formula | C8H13NO5S2 |
| Molecular Weight | 267.323 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.erdosteine.net/Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf
Sources: http://www.erdosteine.net/
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/18046899, https://www.old.health.gov.il/units/pharmacy/trufot/alonim/ERDOTIN_dr_1322978767512.pdf
Erdosteine is an antioxidant compound developed by Edmond Pharma and approved in Europe for the treatment of chronic bronchitis and COPD. Erdosteine has two thiol groups and is believed to act as a free radicals scavenger (through the formation of the active metabolite I, N-thiodiglycolylhomocysteine). Also the drug effect may be due to the inhibition of the activity of elastase enzyme and its interaction with mucosa. The drug got Orphan Drug designation by FDA for the treatment of bronchiectasis.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0070254 |
|||
Target ID: P08246 Gene ID: 1991.0 Gene Symbol: ELANE Target Organism: Homo sapiens (Human) |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ERDOTIN Approved UseMucolytic agent in acute and chronic respiratory diseases. |
|||
| Primary | ERDOTIN Approved UseMucolytic agent in acute and chronic respiratory diseases. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.419 μg/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.594 μg/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.34 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.15 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.45 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.17 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.492 μg × h/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.523 μg × h/mL |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.55 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.32 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
12.23 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.478 h |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.603 h |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERDOSTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
ERDOSTEINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.68 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2126836/ |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: THEOPHYLLINE |
HOMOCYSTEINE,N-[[(CARBOXYMETHYL)THIO]ACETYL]- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Association between lung function and exacerbation frequency in patients with COPD. | 2010-12-09 |
|
| Effects of sulphurous water on human neutrophil elastase release. | 2010-12 |
|
| Combination antioxidant effect of α-tocoferol and erdosteine in ischemia-reperfusion injury in rat model. | 2010-09 |
|
| Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. | 2010-08 |
|
| Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide. | 2010-07-10 |
|
| Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study. | 2010-06 |
|
| Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. | 2010-04 |
|
| Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study. | 2010-04 |
|
| The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. | 2010-04 |
|
| Raft of results energizes researchers. | 2010-03-11 |
|
| Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. | 2010-02-08 |
|
| Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. | 2010-01-06 |
|
| Erdosteine in renal ischemia-reperfusion injury: an experimental study in pigs. | 2010-01 |
|
| Free radical scavenging activity of erdosteine metabolite I investigated by electron paramagnetic resonance spectroscopy. | 2010 |
|
| The protective effect of erdosteine on vancomycin-induced pancreatic damage in rats. | 2009-11 |
|
| Antioxidant systems and oxidative stress in the testes. | 2009-10-02 |
|
| Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury. | 2009-08 |
|
| Erdosteine modulates radiocontrast-induced hepatotoxicity in rat. | 2009-04 |
|
| Protective effect of sulfhydryl-containing antioxidants against ischemia/reperfusion injury of prepubertal rat intestine. | 2009-04 |
|
| Erdosteine: its relevance in COPD treatment. | 2009-03 |
|
| The protective effect of erdosteine on short-term global brain ischemia/reperfusion injury in rats. | 2009-02-01 |
|
| [Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin]. | 2009 |
|
| Antioxidant intervention of smoking-induced lung tumor in mice by vitamin E and quercetin. | 2008-12-20 |
|
| Antioxidant therapeutic advances in COPD. | 2008-12 |
|
| Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression. | 2008-11-05 |
|
| Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. | 2008-10 |
|
| Erdosteine for COPD exacerbations. | 2008-10 |
|
| Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats. | 2008-09 |
|
| The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of hippocampal neural cells. | 2008-08-01 |
|
| Effects of erdosteine on acetaminophen-induced hepatotoxicity in rats. | 2008-07 |
|
| Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. | 2008-06-13 |
|
| High-throughput determination of fudosteine in human plasma by liquid chromatography-tandem mass spectrometry, following protein precipitation in the 96-well plate format. | 2008-05-01 |
|
| The effects of erdosteine on lung injury induced by the ischemia-reperfusion of the hind-limbs in rats. | 2008-04 |
|
| Renoprotective effect of erdosteine in rats against gentamicin nephrotoxicity: a comparison of 99mTc-DMSA uptake with biochemical studies. | 2008-01 |
|
| The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. | 2008 |
|
| [Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin]. | 2008 |
|
| Erdosteine: antitussive and anti-inflammatory effects. | 2008 |
|
| Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. | 2008 |
|
| Antioxidant effect of sulphurous thermal water on human neutrophil bursts: chemiluminescence evaluation. | 2008 |
|
| Erdosteine ameliorates lung injury induced by transient aortic occlusion in rats. | 2007-12-20 |
|
| Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. | 2007-12 |
|
| The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats. | 2007-09-24 |
|
| Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. | 2007-09 |
|
| Mucoactive agents for airway mucus hypersecretory diseases. | 2007-09 |
|
| Protective effects of erdosteine and vitamins C and E combination on ischemia-reperfusion-induced lung oxidative stress and plasma copper and zinc levels in a rat hind limb model. | 2007-07 |
|
| Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. | 2007 |
|
| Future therapeutic treatment of COPD: struggle between oxidants and cytokines. | 2007 |
|
| Antioxidant therapies in COPD. | 2006 |
|
| Role of mucolytics in the management of COPD. | 2006 |
|
| Pharmacological treatment of chronic obstructive pulmonary disease. | 2006 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 18:19:26 GMT 2025
by
admin
on
Wed Apr 02 18:19:26 GMT 2025
|
| Record UNII |
PQ4H3CJ9NU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00923725
Created by
admin on Wed Apr 02 18:19:26 GMT 2025 , Edited by admin on Wed Apr 02 18:19:26 GMT 2025
|
PRIMARY | |||
|
PQ4H3CJ9NU
Created by
admin on Wed Apr 02 18:19:26 GMT 2025 , Edited by admin on Wed Apr 02 18:19:26 GMT 2025
|
PRIMARY | |||
|
121213-21-6
Created by
admin on Wed Apr 02 18:19:26 GMT 2025 , Edited by admin on Wed Apr 02 18:19:26 GMT 2025
|
PRIMARY | |||
|
10199236
Created by
admin on Wed Apr 02 18:19:26 GMT 2025 , Edited by admin on Wed Apr 02 18:19:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
